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Abstract
Background: The validity, reliability and cross-country comparability of summary measures of population health
(SMPH) have been persistently debated. In this debate, the measurement and valuation of nonfatal health
outcomes have been defined as key issues. Our goal was to quantify and decompose international differences in
health expectancy based on health-related quality of life (HRQoL). We focused on the impact of value set choice
on cross-country variation.
Methods: We calculated Quality Adjusted Life Expectancy (QALE) at age 20 for 15 countries in which EQ-5D
population surveys had been conducted. We applied the Sullivan approach to combine the EQ-5D based HRQoL
data with life tables from the Human Mortality Database. Mean HRQoL by country-gender-age was estimated using
a parametric model. We used nonparametric bootstrap techniques to compute confidence intervals. QALE was
then compared across the six country-specific time trade-off value sets that were available. Finally, three
counterfactual estimates were generated in order to assess the contribution of mortality, health states and health-
state values to cross-country differences in QALE.
Results: QALE at age 20 ranged from 33 years in Armenia to almost 61 years in Japan, using the UK value set. The
value sets of the other five countries generated different estimates, up to seven years higher. The relative impact of
choosing a different value set differed across country-gender strata between 2% and 20%. In 50% of the country-
gender strata the ranking changed by two or more positions across value sets. The decomposition demonstrated a
varying impact of health states, health-state values, and mortality on QALE differences across countries.
Conclusions: The choice of the value set in SMPH may seriously affect cross-country comparisons of health
expectancy, even across populations of similar levels of wealth and education. In our opinion, it is essential to get
more insight into the drivers of differences in health-state values across populations. This will enhance the
usefulness of health-expectancy measures.
Background
Summary measures of population health (SMPH) have
been calculated to represent the health of a particular
population in a single number, combining information on
fatal and nonfatal health outcomes [1,2]. SMPH have been
applied to various purposes, e.g., to monitor changes in
population health over time, to compare population health
across countries, to investigate health inequalities (the dis-
tribution of health within a population), and to quantify
the benefits of health interventions in cost effectiveness
analyses [3-5]. In this study, we focus on using SMPH to
compare the level of health across populations.
Although different types of SMPH have been developed
[6-10], they usually comprise three elements: information
on mortality, nonfatal health outcomes, and health-state
values. Health-state values reflect the impact of nonfatal
health outcomes on a cardinal scale, commonly compris-
ing a value of 1 for full health and a value of 0 for a state
equivalent to death. In SMPH, the number of years lived
in a particular population (taken from life tables) is com-
bined with information on the (proportional) prevalence
of health states or diseases and the value of these nonfatal
health outcomes. In this way, the number of life years
lived in a population is transformed into the number of
healthy life years lived.1 The value sets provide the link
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between the information on nonfatal health outcomes
and the information on mortality.
There has been much debate on SMPH, in particular
regarding the validity, reliability, and cross-country com-
parability of different methods. A complete discussion on
the pros and cons of different methods is beyond the
scope of this paper and can be found elsewhere [6,11,12].
In short, crucial and persistent issues have been the mea-
surement and valuation of nonfatal health outcomes and
the incorporation of other values such as discounting or
equity. In cases where SMPH are used to compare popu-
lation health across countries, it is essential to use the
same concepts and measurement methods for mortality,
nonfatal health outcomes, and value sets across countries.
Furthermore, it is crucial to understand in what way the
method chosen may affect cross-country variation in the
summary measure.
In this study we performed a cross-country compari-
son of Quality Adjusted Life Expectancy (QALE). We
included information on health-related quality of life
(HRQoL) to represent nonfatal health outcomes. EQ-5D
(HRQoL) population surveys were used, and we
included the 15 countries in which an EQ-5D popula-
tion survey had been conducted. The EQ-5D is a stan-
dardized and validated questionnaire for measuring
HRQoL. It comprises five dimensions such as mobility
and self-care. The information on HRQoL, in combina-
tion with one of the available value sets, can be used to
calculate QALE. As far as we know, a HRQoL-based
approach has rarely been used in SMPH [1], particularly
in international comparisons. The approach may prove
interesting, since the value sets are calculated on the
basis of choice-based methods, which have a theoretical
foundation in economic theory [13]. Furthermore, data
requirements of an EQ-5D type of instrument may be
limited compared to other approaches such as using dis-
ease prevalence, particularly in international compari-
sons [14,15]. There are several other validated HRQoL
instruments besides the EQ-5D, such as the SF-36 and
the Health Utility Index mark 2 and mark 3 (HUI-2 and
HUI-3) [16-18]. Muennig et al. used EQ-5D data to esti-
mate Health Adjusted Life Years (HALY) in the Ameri-
can population [19]. They found differences across
income groups, yet they did not provide insight into the
uncertainty in their estimates. In Canada, the HUI was
used to calculate a national SMPH [20,21]. Feeny et al.
used the HUI-3 and a single Canadian value set to com-
pare health expectancy between Canada and the US
[21]. Significant health differences between the two
countries were found. Health-state profiles have also
been included in SMPH in combination with informa-
tion on diseases and disability [7].
Our first aim was to provide more empirical evidence
on international differences in HRQoL-based health
expectancy. Additionally, we aimed to explore the impact
of the value set choice. In the context of international
comparisons, a choice has to be made between country-
specific values and cross-country (global) values. The
issue of value set choice has not been extensively dis-
cussed in the literature, however. It can be argued that if
SMPH serve (international) health system performance
assessments, country-specific value sets are preferred.
Health systems should deliver outcomes in accordance
with the preferences of the population they serve and
whose means are put in use. Country-specific value sets
may not always be available, however. Some have used
foreign value sets, e.g., from neighboring countries. For
example, Feeny et al. compared health-utility-based
health expectancy between the US and Canada using the
Canadian value set for both countries [21]. The authors
remarked this as a limitation because the true preferences
of the US population may not exactly resemble the Cana-
dian values. Some have used a single global value set in
international comparisons. For example, Mathers et al.
calculated Health Adjusted Life Expectancy (HALE) by
combining data on disease incidence (from the WHO
Global Burden of Disease [GBD] study) with, for a subset
of countries, survey data on health states [7]. Global
value sets were applied to both the diseases (values were
called severity weights in this context) and the health
states. International comparisons of disability-adjusted
life years (DALYs) and of disability-adjusted life expec-
tancy (DALE) also used a single value set across countries
[22-24]. It has been argued that the valuation of health
domains shows reasonable consistency across countries,
justifying the use of a global value set from an empirical
perspective [25]. Nevertheless the need for more empiri-
cal evidence was acknowledged. Others did find differ-
ences in disease/disability-related values across countries
and raised doubts about the universality of health values
[26]. Another consideration that could support the use of
global values is that identical interventions on identical
patients will result in different benefits if different value
sets are used. For example, less-healthy (poorer) popula-
tions may experience a smaller impact of health problems
and a smaller benefit from interventions because they are
unaware of better health outcomes. In other words, dif-
ferences in values and expectations would determine sys-
tem performance and could also alter resource allocation
decisions across populations in a way that may be consid-
ered undesirable.
In summary, the literature has demonstrated a need to
improve the understanding of differences in the valuation
of health, also in the context of international compari-
sons of SMPH [25-27]. We aimed to provide more
empirical evidence on the impact of value sets on cross-
country differences in health expectancy. Furthermore,
we aimed to discuss these results in the context of the
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theoretical and methodological issues that have been
raised in the literature.
Methods
Data
We calculated QALE in 15 countries using individual-level
EQ-5D survey data (provided by Euroqol Group) and life
tables from the Human Mortality Database (HMD) [28].
The HMD did not provide life tables for Armenia and
Greece, for which we instead used WHO life tables [29].
The countries were selected on the basis of EQ-5D data
availability. The EQ-5D surveys were conducted between
1993 and 2002 (see Additional file 1). All surveys used the
standard EQ-5D setup. The translation process of the
EQ-5D surveys followed the guidelines proposed in the
international literature [30]. Survey respondents were non-
institutionalized persons older than 18 years. Sample size
varied between 400 and 10,000 observations per country
(see Additional file 1). We excluded 2,989 observations
with missing values in at least one of the EQ-5D dimen-
sions because HRQoL could not be calculated in these
cases. Consequently 41,562 observations/individuals
remained in the pooled dataset. We used life tables from
the year 2000 for all countries.
The value sets used to weight health states were all
based on the time trade-off (TTO) elicitation technique
and were taken from the literature. TTO-based valua-
tion studies had been conducted in Germany, Japan, the
Netherlands, Spain, the UK, and the US (see Table 1)
[16,31-35]. The TTO method is considered the most
appropriate (consistent) method to elicit preferences,
compared to the Standard Gamble technique or the
Visual Analogue Scale, for example [36].
HRQoL
The EQ-5D comprises five domains: mobility, self-care,
usual activities, pain/discomfort, and anxiety/depression.
Each domain contains three levels: no problems (1),
some problems (2), and extreme problems (3). For
example, a respondent may report no problems in mobi-
lity, self-care, usual activities, and pain/discomfort, and
some problems in anxiety/depression. Generally the five
answers are transformed into a single HRQoL index as
follows:
HRQoL = 1 −
∑
jk
(αcjkdjk + βcN2 + γcN3) (1)
where acjk = value of EQ-5D domain j and level k for
country c; djk = dummy for health state j and level k; bc
= value of having some or severe problems in at least
one health domain (dummy N2) for country c; and gc =
value of having severe problems in at least one health
domain (dummy N3) for country c.
The US value set was based on a different formula
[35]:
HRQoL = 1 −
∑
jk
(αcjkdjk + φcD1 − ϕcI2square + χcI3 + ψcI3square) (2)
where D1 = number of domains with some or extreme
problems beyond the first, I2square equals the square of
the number of domains at level 2 beyond the first, and
I3square equals the square of the number of domains at
level 3 beyond the first. This model was chosen in the
US because it provided the best fit for the data [35].
Additionally, in contrast to the other value sets, the US
model was meant to take account of the marginal
changes in HRQoL associated with having some or
extreme problems in additional domains.
Equation (1) and equation (2) show that the maximum
HRQoL equals 1. The values acjk reflect the HRQoL
reduction associated with having some problems or
severe problems in each EQ-5D domain. These prefer-
ences may differ across countries as shown in Table 1
by the difference in minimum HRQoL (see also
[34,37,38]). Figure 1 demonstrates the relative value of
each EQ-5D dimension for the five value sets that are
based on equation (1). For example, it shows that, com-
pared to Dutch residents, people in the UK attached
Table 1 Characteristics of the TTO value sets
Country Reference Elicitation year Minimum HRQoL
Germany Greiner (2005) 1997-1998 -0.205
Japan Tsuchiya (2002) 1998 -0.111
Netherlands Lamers (2005) 2003 -0.329
Spain Badia (2001) 1996 -0.654
UK Dolan (1997) 1993 -0.594
US Shaw (2005) 2002 -0.102
Figure 1 Value of the EQ-5D domains and levels. 1The US values
are not shown because they are based on a different formula.
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greater value to having some or severe health problems
in all domains except anxiety (see [33]). Consequently,
minimum HRQoL was lower in the UK (-0.594 vs.
-0.329).
Analysis
We used the Sullivan approach to combine mortality
and nonfatal health outcomes and to calculate QALE
[39]. The life tables comprised current death rates and
conditional probabilities of death by country, gender,
and age group (mostly five-year age groups). These
probabilities were used to calculate the number of life
years lived per age group for a hypothetical cohort. We
multiplied the number of life years, as given in the
HMD life tables, with the mean HRQoL as predicted by
the parametric model described underneath, in order to
calculate the number of healthy life years. Finally, the
total number of healthy life years from age × was
divided by the number of survivors in the hypothetical
cohort at age × to calculate QALE at age x. We
excluded age groups under 20 years, because the EQ-5D
surveys were conducted among individuals older than
18 years. In addition, we were unable to differentiate
HRQoL in the age groups over 85 years, because the
maximum age of respondents was 90 in almost all sur-
veys. Equation (3) is a formal representation of the
QALE.
QALEc,g,a =
∑z
a (LYc,g,a ∗ HRQoLc,g,a)
lc,g,a
(3)
LYc,g,a equals total number of life years lived in coun-
try c, gender g, and age group a;
HRQoLc,g,a equals average (predicted) HRQoL by
country c, gender g, and age group a;
lc,g,a equals number of survivors in the life table cohort
for country c, gender g, and age group a; and z equals
the last open-ended age interval of the life table.
HRQoLc,g,a was calculated in three steps: 1) we calcu-
lated HRQoL at the individual level using equation (1); 2)
we estimated the predicted HRQoL at the individual level
using a multiple regression model; and 3) we computed
the mean predicted HRQoL by country, gender, and age.
In step 2, we estimated a multiple regression model with
HRQoL as dependent variable (in the range [minimum,
1]) and age, gender, country dummies, and education
level as independent variables. We estimated the model
to fully exploit the information available in the pooled
dataset and to explore the relationship between HRQoL
and respondent characteristics (Additional file 2 shows
that there is almost no difference between QALE using
observed HRQoL and QALE using predicted HRQoL).
Previous studies have shown that HRQoL is associated
with demographic and socioeconomic characteristics
such as age, gender, education, income, and race (e.g.,
[19,40-42]). The EQ-5D surveys provided information on
the respondents’ age (the average age was 47 in the
pooled dataset), gender (46% male), country, and level of
education (primary education 31%, secondary education
57%, and university level 12%). The variables socioeco-
nomic status and smoking status were not used because
of high nonresponse rates (43% and 47% respectively). It
was expected that the relationship between HRQoL and,
for example, age differed by gender and country. There-
fore interaction terms between country, gender, and age
were included in the model. We used nonparametric
bootstrap techniques to calculate 95% confidence inter-
vals. As discussed in Pullenayegum et al., regression
models that use this type of outcome measure need to
take heteroscedasticity and a nonnormal distribution into
account [43]. Pullenayegum et al. showed that OLS
regression with nonparametric bootstrap can give ‘accep-
table adequacy’ of the confidence intervals with these
data. We also tested alternative models, a tobit model
and a two-part model, which have been used to model
skewed and truncated data. The outcomes of these mod-
els did not alter the main results and conclusions (these
regression results can be obtained through the corre-
sponding author).
Finally, we computed counterfactual estimates in order
to explore the contribution of mortality, health states,
and health-state valuation to cross-country variation in
QALE. In this part of the study, we only included the
six countries for which value sets had been established
(Table 1). As a result, six sets of counterfactual esti-
mates were generated. In each set, a different country
was used as reference country. Suppose we use Germany
as reference country. Then, we imputed mortality rates,
health-state profiles, and values from Germany into
QALE of, for example, Spain. Subsequently, we investi-
gated the associated change in QALE for Spain in com-
parison to QALE based on Spanish mortality, health
states, and values.
In the first counterfactual estimate we used country-spe-
cific value sets, country-specific EQ-5D health states, and
death rates of the reference country. In other words, we
imputed LY and l of the reference country in equation (3).
The difference between this counterfactual QALE and the
original QALE (based on country-specific mortality, health
states, and values) revealed the contribution of mortality.
With the second counterfactual QALE we estimated the
impact of health states using country-specific value sets,
country-specific death rates, and EQ-5D health states of
the reference country. Now the HRQoL component in
equation (3) was based on country-specific values ac,j,k
and on the health state profiles djk of the reference coun-
try. The difference between this counterfactual QALE and
the original QALE showed the contribution of health
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states. The third counterfactual estimate comprised coun-
try-specific EQ-5D health states, country-specific death
rates, and the value set of the reference country. We
imputed the values a of the reference country in equation
(1). Subsequently, QALE was estimated using equation (3)
and the difference between this counterfactual QALE and
the original QALE demonstrated the impact of value sets.
Results
Regression results
Table 2 presents the results of the regression model
(using UK values). The table shows that HRQoL declined
with age, although the relationship was not linear (age,
age squared, and age cubic were jointly significant). The
gender-age interaction term shows that the age effect dif-
fered between men and women: the reduction in HRQoL
over age was somewhat smaller for males. In addition,
the regression results showed significant country effects
and cross-country differences in the impact of age and
gender. The country dummies and interaction terms
were jointly significant. HRQoL was also positively asso-
ciated with education level.
QALE
Figure 2 shows QALE at age 20 by country and gender
(using UK values). It shows that QALE at age 20 ranged
from 33 years in Armenia (males) to almost 61 years in
Japan (females). The figure shows that QALE at age 20
years was higher for females than for males. Only
Greece showed a higher male QALE, yet the confidence
intervals of the two genders largely overlapped for this
country. The absolute gender difference in QALE ran-
ged between 1.6 years in the US and 4.6 years in
Slovenia.
Value set choice
The former results were calculated using the UK value
set in all countries. Table 3 demonstrates QALE using
different value sets. The table shows that the UK value
set generated the lowest QALE in most (67%) of the
country-gender strata. The German value set generated
the highest QALE in all country-gender strata, with a
maximum difference of 7.2 healthy years (difference in
QALE between the German value set and the UK value
set for females in Armenia). The US value set consis-
tently showed the second-highest QALE. In 60% to 70%
of all country-gender strata, the Spanish value set ranked
third, the Dutch value set ranked fourth, the Japanese
value set ranked fifth, and the UK value set ranked sixth.
The relative change in QALE, as a result of a change in
value set choice, varied between countries. For example,
the difference in QALE between the German value set
and the UK value set was close to 3% for Japanese males,
but more than 20% for Armenian females. We also added
a country ranking (R) by value set and by gender. The
countries at the top end and low end of the ranking
showed a stable position across value sets. In between,
the ranking of the countries was affected to some extent.
Around 50% of the country-gender strata moved two or
more rank-positions across value sets. Notable rank-
changes were found for Belgium (females), Canada
(females), Finland (females), Greece (males), and Sweden
(males).
Table 2 Regression results1
Main effects Coef. P > |z| Interaction terms Coef. P > |z|
Age -0.069 0.000 Gender*age -0.003 0.000
Age squared 0.003 0.004
Age cubic -0.000 0.002 Belgium*age 0.028 0.000
Canada*age 0.027 0.000
Education2 0.040 0.000 Finland*age 0.024 0.000
Gender3 0.010 0.555 Germany*age 0.026 0.000
Greece*age 0.020 0.000
Belgium -0.114 0.003 Hungary*age 0.018 0.000
Canada -0.107 0.000 Japan*age 0.032 0.000
Finland -0.078 0.010 Netherlands*age 0.031 0.000
Germany -0.086 0.009 New Zealand*age 0.027 0.000
Greece 0.018 0.700 Slovenia*age 0.020 0.000
Hungary -0.025 0.372 Spain*age 0.029 0.000
Japan -0.085 0.042 Sweden*age 0.033 0.000
Netherlands -0.125 0.000 UK*age 0.026 0.000
New Zealand -0.104 0.003 US*age 0.025 0.000
Slovenia -0.114 0.003
Spain -0.090 0.001 Belgium*gender -0.001 0.966
Sweden -0.189 0.000 Canada*gender -0.015 0.490
UK -0.094 0.001 Finland*gender 0.008 0.689
US -0.132 0.000 Germany*gender -0.008 0.724
Greece*gender -0.017 0.496
Hungary*gender -0.024 0.160
Japan*gender -0.009 0.701
Netherlands*gender -0.015 0.397
New Zealand*gender 0.015 0.502
Slovenia*gender 0.019 0.367
Spain*gender -0.024 0.158
Sweden*gender 0.036 0.037
UK*gender 0.023 0.215
US*gender -0.014 0.447
Constant 1,138
Adj R-squared 0.16
N 40,650
¹ Standard errors were calculated using non-parametric bootstrap technique
2 Education levels: 1 = low (primary); 2 = medium (secondary); 3 = high
(university)
3 Gender: 0 = male; 1 = female
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QALE decomposition
Counterfactual estimates were generated in order to
explore the role of mortality, health states, and health-
state values in cross-country differences. Figure 3
demonstrates the results. Each of the six countries
involved (Germany, Japan, Netherlands, Spain, UK, and
US) appears once as reference country in the counter-
factual scenarios. As a result, six figures are shown. The
figure demonstrates that the impact of the different
QALE components varied substantially across countries.
For example, the top-left graph demonstrates the contri-
bution of mortality, EQ-5D health states, and health-
state values to the difference in QALE with the UK. It
shows that mortality rates explained the major part of
the QALE difference with the UK for Japanese females
and Spanish females. Differences in terms of valuation
explained most of the difference in QALE with the UK
for Germany and the US. Differences in EQ-5D health
states explained the greater part of the variation in
QALE for males in Japan, the Netherlands, and Spain.
The figure shows that the differences in QALE with
Germany are largely explained by the valuation compo-
nent for all countries.
Discussion and conclusions
In this study we performed an international comparison
of HRQoL-based health expectancy. We found that
QALE at age 20 ranged between 33 years in Armenia
and almost 61 years in Japan. Generally, female QALE
was higher than male QALE within this set of countries.
In terms of QALE, Hungary and Slovenia performed
better than Armenia, yet worse in comparison to the
other countries. The relatively low health expectancy for
a country such as Armenia may be expected given its
lower levels of health spending and national income and
its different socioeconomic circumstances. The United
States performed worse in terms of QALE compared to
the other western high-income countries in the dataset.
Many studies have found such unfavorable health out-
comes in the US and several explanations for this phe-
nomenon have been given, such as an inefficient health
care system, substantial disparities in the population in
terms of access to health care, or behavioral factors
(unhealthy diets) [44,45].
In the final part of the analysis, we decomposed the dif-
ference in QALE using counterfactual scenarios. It was
shown that the relative contribution of mortality, health
states, and health-state values differed among countries.
For example, the high QALE for Japanese males was to a
large extent a result of a low prevalence of health pro-
blems in EQ-5D domains. In turn, the better average
health of Spanish females was largely explained by lower
mortality rates. Interestingly, in various cases the EQ-5D
profiles showed a greater contribution to differences in
QALE than differences in mortality. Lower mortality did
go hand in hand with better HRQoL, although there
were exceptions. For example, Dutch females had a lower
life expectancy than Spanish females, yet they experi-
enced fewer health problems in EQ-5D domains. As a
result, the difference in HRQoL-based health expectancy
was smaller than the difference in life expectancy
between these two countries. The decomposition con-
firmed that international comparisons of health expec-
tancy, based on country-specific values, are influenced
substantially by differences in value sets.
Differences in health expectancy across countries may
stem from various factors, among which methodological
issues and cultural differences play a role. Amid the three
main SMPH elements (mortality, nonfatal health out-
comes, and valuation) we focus on the value sets first. A
remarkable result was the difference in QALE across the
six TTO value sets. The German value set generated
QALE up to seven years higher than the UK value set.
The ranking of countries varied to a lesser extent across
value sets, particularly in the high-performing or low-
performing countries. We did find rank switches in the
group of average performers. This may be expected
because the differences in QALE were relatively small in
this middle group, showing various overlapping confi-
dence intervals (see Figure 2). Therefore, the ranking of
these country-gender strata is particularly sensitive to the
value-set choice. Around 50% of the country-gender
strata showed a rank-change of two or more positions
across value sets. Interestingly, the relative change in
QALE associated with the value set choice differed across
countries. The impact was greatest in low-performing
countries such as Armenia, Hungary, and Slovenia.
We also found that the ranking of countries did not
30
40
50
60
ARM BEL CAN FIN GER GRE HUN JAP NET NZL SLV SPA SWE UK US
Figure 2 Quality Adjusted Life Expectancy at 20 years by country
and gender1. 1Confidence interval based on nonparametric
bootstrap technique. Blue: females, Red: males.
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consistently improve when local values were used. For
example, Germany did not reach a higher rank in the
German value set compared to the ranking in which
Japanese values were used.
In the literature, the variation in health valuation has
largely been explained by methodological differences
across valuation studies and differences in the level of
wealth and the level of education among populations
[27]. In our case the available value sets represented the
preferences of Western countries of similar levels of edu-
cation and similar levels of wealth. Although we cannot
exclude that methodological differences played a role, we
argue that these cannot fully explain the variation that
was found (see also [46]). All studies were conducted
using face-to-face interviews, applied the TTO technique
to elicit values, and included nationally-representative
samples. In order to determine the valuation function,
they used similarly specified least squares regression
models representing the relationship between the TTO
outcome and EQ-5D domains-levels and took account of
within-individual error correlation [46]. The main differ-
ence was the model used in the US, which included a dif-
ferent specification of the N2 and N3 interaction terms
and the marginal HRQoL effects. The US value set took
account of a decrease in the marginal reduction in
HRQoL associated with further increases in the number
of domains with any problems or extreme problems. Still,
the extent to which the US valuation function generated
different HRQoL scores not only depended on the inter-
action terms and marginal effects, but also on the values
attached to the individual domains and levels. Additional
file 3 shows for each value set the HRQoL score
Table 3 QALE at age 20 years using different value sets plus a country ranking (R)1
Value set Germany Value set Japan Value set Netherlands Value set Spain Value set UK Value set US
QALE R QALE R QALE R QALE R QALE R QALE R
Males
ARM 39.13 15 36.93 15 34.91 15 35.99 15 33.62 15 37.85 15
BEL 50.88 9 47.22 10 48.45 10 49.19 10 47.47 10 49.23 10
CAN 52.72 2 49.00 5 49.89 6 50.76 5 49.07 5 51.02 4
FIN 49.71 11 46.35 12 48.00 11 47.97 11 46.57 11 48.47 11
GER 50.68 10 48.21 9 49.24 7 49.51 8 47.98 8 49.83 9
GRE 51.20 7 50.17 4 49.95 5 49.72 7 49.54 4 50.81 5
HUN 44.34 14 41.83 13 42.07 14 42.60 14 41.42 13 43.12 14
JAP 56.14 1 54.68 1 55.19 1 55.43 1 54.70 1 55.46 1
NET 52.60 5 50.25 3 51.33 2 51.52 3 50.34 2 51.66 2
NZL 52.27 6 48.82 6 50.13 4 50.45 6 48.96 6 50.74 6
SLV 46.04 13 41.36 14 42.74 13 42.73 13 41.37 14 43.96 13
SPA 52.66 3 50.43 2 51.17 3 51.57 2 50.27 3 51.65 3
SWE 52.63 4 48.37 8 49.11 8 50.84 4 48.29 7 50.48 7
UK 50.93 8 48.60 7 48.95 9 49.22 9 47.89 9 49.94 8
US 49.67 12 46.61 11 47.33 12 47.90 12 46.20 12 48.39 12
Females
ARM 42.74 15 39.43 15 37.03 15 38.87 15 35.51 15 40.96 15
BEL 55.14 7 50.77 10 52.24 8 53.08 6 50.73 10 53.17 10
CAN 55.50 5 50.83 9 52.05 10 52.96 9 50.73 9 53.51 7
FIN 54.70 10 50.95 8 52.69 6 52.49 10 50.87 8 53.36 8
GER 55.12 8 51.22 7 52.12 9 53.06 7 50.88 7 53.35 9
GRE 51.41 13 49.98 11 50.23 11 50.23 11 48.91 11 50.80 12
HUN 49.69 14 46.01 14 45.65 14 46.89 14 44.78 14 47.87 14
JAP 61.01 1 58.68 1 59.53 1 59.87 1 58.54 1 59.99 1
NET 55.35 6 52.10 4 53.44 5 53.59 5 51.94 5 54.11 5
NZL 56.45 4 51.99 5 53.55 4 54.11 4 52.32 4 54.51 4
SLV 51.88 12 46.03 13 47.64 13 47.60 13 45.99 13 49.22 13
SPA 56.67 3 53.80 2 53.93 2 54.80 3 52.76 2 55.32 2
SWE 56.75 2 52.97 3 53.70 3 55.04 2 52.67 3 54.93 3
UK 54.98 9 51.75 6 52.27 7 52.98 8 51.23 6 53.56 6
US 52.45 11 48.92 12 49.18 12 50.03 12 47.79 12 50.93 11
1 QALE in bold where country-specific values were used.
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associated with certain health states to exemplify the
differences.
Consequently, we argue that a more conceptual discus-
sion is needed. Cross-country variation in values may
reflect cultural differences or differences in the availability
of certain social services (and therefore the perceived/
expected impact of health impairments). Naturally, health-
state values also differ among individuals [47]. It may be
argued that national or global value sets should cover this
within-population variation in terms of values. In other
words, the samples in elicitation studies need to be repre-
sentative along the relevant population characteristics
(similar to the other elements of SMPH). The cross-
national differences in values need to be taken into
account in the context of health-system-performance
assessments and international comparisons of population
health. In such studies, country-specific value sets may be
preferred, since each health system should deliver out-
comes according to the preferences of the population it
serves and whose means are put in use. Moreover, the
varying impact of health problems across countries needs
to be accounted for. Some previous international compari-
sons of SMPH have used global value sets, based on the
argument that health values are reasonably consistent
across countries. However, the result of this study, similar
to, for example, Üstün et al. [26], points to the contrary
and shows that variation in values may affect SMPH out-
comes. A drawback of using country-specific value sets is
that they may not always be available, as was experienced
in this study and in previous studies (e.g. [21]). In our opi-
nion, the best solution is to calculate health expectancy by
different foreign value sets and to compare the differences
(as in Table 3). Additionally, the use of country-specific
value sets in international comparisons may deserve close
scrutiny from an equity perspective, particularly if there is
a relationship among values, true health status, and level
of wealth. Populations with less exposure to what constitu-
tes “full health” may assign lower values, i.e., a smaller loss
in terms of HRQoL, to certain health problems. As a
result, a particular health intervention will generate fewer
benefits in these populations. From an equity perspective,
this may be considered undesirable. This argument has
not been tested empirically though, and may be less rele-
vant when only high-income countries of similar levels of
health are included, as in our study.
The issue of value-set choice not only pertains to
HRQoL-based health expectancy. All SMPH using mul-
tiple health states, diseases, levels of disability, or other
Figure 3 Contribution of mortality, EQ-5D health states and value sets to cross-country differences in QALE1. 1The y-axis shows the
difference in quality adjusted life years between the QALE that comprised country-specific components and each counterfactual estimate. Blue:
mortality, Red: health states, Green: values.
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morbidity measures use a valuation function or a set of
weights. Only measures such as disability-free life expec-
tancy do not comprise value sets. Such approaches clas-
sify people in two groups: with or without disability or
disease. In that case you simply multiply the proportion
without any disability with the number of life years lived
in a particular stratum. Obviously these are rather crude
methods that neglect differences in severity levels.
Two other issues need to be raised regarding the valua-
tion part of SMPH. First, a plus of the EQ-5D type
instrument, particularly in case an economic perspective
is required, may be that value sets have been elicited
using a choice-based method (TTO technique). Choice-
based methods are considered the preferred method
among economists to elicit people’s preferences. The
extent to which the elicitation method affects cross-
country differences is largely unknown. Some have
argued that different elicitation methods generate a
rather similar cross-country variation in terms of values,
but more research is needed on this issue [47]. Secondly,
we need to address the question of whose values should
be used. The value sets we used all represented general
population values. Various authors have compared popu-
lation values with patient values [48-51]. From an eco-
nomic perspective, population values may be preferred,
since health systems consume public means and should
therefore allocate their resources and outcomes accord-
ing to the preferences of the general population [48].
However, it was found that the general public attaches a
much greater loss in terms of HRQoL to particular health
problems than patients do. Although patients are better
informed about the impact of morbidity, the adaptation
effect is present among them [52,53]. Expert opinion has
also been applied in previous international studies on
SMPH [24]. The question is to what extent experts are
able to assess the impact of different health states or dis-
eases on people in general as well as for different popula-
tions. As a result this discussion appears unresolved.
As demonstrated by the decomposition, differences in
QALE are also affected by differences in health states.
Two major measurement issues should be discussed in
this respect. First, although all studies used the same stan-
dardized EQ-5D instrument, the mode of administration
differed across studies. It has been shown that telephone
surveys in particular may generate more positive HRQoL
scores compared to self- or interviewer-administered sur-
veys [54]. The surveys included in our study were con-
ducted as face-to-face interviews (Armenia, Greece, Japan,
Spain, and UK) or self-administered postal interviews
(other countries). Only part of the German data was based
on a telephone survey. A second major measurement issue
regarding the measurement of nonfatal health outcomes is
response heterogeneity. People who are in an objectively
equal health state may respond differently to the same
health question. Response heterogeneity can be explained
by differences in norms and expectations, in awareness,
and in access to health care across populations. It may
affect the validity and the cross-population comparability
of all SMPH using self-reported health data (in terms of
health states, disability, or disease) [55]. At the same time,
the effect of response heterogeneity may somewhat be
dampened if similar mechanisms also play a role in the
valuation of nonfatal health outcomes. Some have argued
that response heterogeneity may be less of a problem if
different severity levels are included in the morbidity mea-
sure, since most threshold issues arise at the lower-valued
mild-severity levels [1]. Moreover, the problem may be
greater in self-rated general health questions, and some
authors even used EQ-5D type of questions as more objec-
tive health measures [56,57]. Still, it remains unclear to
what extent the reporting of EQ-5D health states, and our
international comparison, have been subject to response
bias. Whether response bias in the measurement of
morbidity is related to the variation in the valuation of
morbidity needs further investigation.
From a practical point of view, HRQoL-type of data may
be preferred, since this approach may turn out to be less
resource-intensive in terms of data gathering and data
analysis than, for example, disease-based methods [22].
The latter approach requires information on many types
of diseases and on the impact of all diseases in terms of
disability. At an international level, data availability may be
limited, which could cause less accuracy of the results.
Furthermore, the presence of comorbidity complicates
disease-based calculations [58]. In turn, an advantage of
disease-based measures may be that clinical records or
administrative records on the prevalence of diseases
can be used. Such data do not suffer from self-report
problems.
The following should be kept in mind while interpret-
ing our results. First, the EQ-5D surveys were conducted
in different years. This also holds for the value sets that
were used, whereas preferences may change over time. It
is unclear whether this is the case and to what extent this
may have affected the results. We did see that value sets
from similar years still showed substantial differences
such as those from the Netherlands and the US or those
from Germany and Japan. Future research could clarify
to what extent health-related preferences change over
time. Secondly, certain population groups were not
included in the EQ-5D samples, such as inhabitants
younger than 20 years and, in most surveys, people older
than 85. Therefore we did not calculate QALE at birth
and were unable to differentiate HRQoL within the 85-
plus group. In addition, the surveys did not include the
institutionalized population. However, due to a lack of
comparable data, it is unclear to what extent this influ-
enced the cross-country variation. Further, it was unclear
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whether all potential determinants of HRQoL were repre-
sented sufficiently. Thirdly, we did not take uncertainty
in mortality into account because this information was
not included in WHO life tables. However, there will be
little uncertainty in life tables given the large population
size. Consequently, the uncertainty in health expectancy
particularly arises in the morbidity part of these measures
[21]. Finally, as discussed before, different researchers
may have used slightly different protocols and analyses
which may have affected the differences in value sets [46].
In conclusion, we recommend that future interna-
tional comparisons on SMPH profoundly discuss their
value-set choice, including the theoretical and practical
issues, and perform sensitivity analyses where possible
and necessary. In addition, more qualitative research on
the determinants of differences in valuation within and
across populations is needed. This will improve the
interpretation and the usefulness of HRQoL-based, and
other, summary measures of population health.
Endnote
1A simplified example: suppose that the life expectancy
at birth of a population is equal to 80 years. Further-
more assume that half of the population lives in perfect
health for 80 years, and the other half lives in an imper-
fect health state for 80 years. If the value of this imper-
fect health state is 0.5 then half of the population will
live 80 healthy years and half of the population will live
80*0.5 = 40 healthy years. Consequently health expec-
tancy of the entire population will be 60 years.
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